General MedicationsORALStandard

GENVOYA

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Standard Dose

150MG;150MG;200MG;EQ 10MG BASE

Max Dose

Refer to approved labeling

Primary Use

Review priority: PRIORITY Marketing status: Prescription

Summary

Approval overview GENVOYA is listed in Drugs@FDA under application 207561 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE Form and strength TABLET;ORAL - 150MG;150MG;200MG;EQ 10MG BASE Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2022-01-07 00:00:00.

Structured Monograph

Clinical summary

Approval overview GENVOYA is listed in Drugs@FDA under application 207561 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE Form and strength TABLET;ORAL - 150MG;150MG;200MG;EQ 10MG BASE Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2022-01-07 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: PRIORITY

Interaction Notes

No interaction notes stored yet.